Cargando…
CAR-NK cell therapy for glioblastoma: what to do next?
Glioblastoma is a malignant tumor with the highest morbidity and mortality in the central nervous system. Conventional surgical resection combined with radiotherapy or chemotherapy has a high recurrence rate and poor prognosis. The 5-year survival rate of patients is less than 10%. In tumor immunoth...
Autores principales: | Xiong, Qi, Zhu, Jiao, Zhang, Yong, Deng, Hongxin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315652/ https://www.ncbi.nlm.nih.gov/pubmed/37404752 http://dx.doi.org/10.3389/fonc.2023.1192128 |
Ejemplares similares
-
Autologous, allogeneic hematopoietic cell transplantation and CAR-T/NK therapy: what is their real importance in PTCL?
por: Couto, Samuel C. F., et al.
Publicado: (2023) -
CAR‐NK cells: the next wave of cellular therapy for cancer
por: Daher, May, et al.
Publicado: (2021) -
From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021) -
CAR-NK Cell: A New Paradigm in Tumor Immunotherapy
por: Marofi, Faroogh, et al.
Publicado: (2021) -
Retraction: CAR-NK Cell: a new paradigm in tumor immunotherapy
Publicado: (2023)